These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11020297)

  • 1. Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: implications for recognition by tumor-infiltrating lymphocytes.
    Guichard G; Zerbib A; Le Gal FA; Hoebeke J; Connan F; Choppin J; Briand JP; Guillet JG
    J Med Chem; 2000 Oct; 43(20):3803-8. PubMed ID: 11020297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
    J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and antigenic properties of reduced peptide bond analogues of an immunodominant epitope of the melanoma MART-1 protein.
    Quesnel A; Zerbib A; Connan F; Guillet JG; Briand JP; Choppin J
    J Pept Sci; 2001 Mar; 7(3):157-65. PubMed ID: 11297352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.
    Benlalam H; Linard B; Guilloux Y; Moreau-Aubry A; Derré L; Diez E; Dreno B; Jotereau F; Labarrière N
    J Immunol; 2003 Dec; 171(11):6283-9. PubMed ID: 14634146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
    Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
    Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
    Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
    Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
    Valmori D; Gervois N; Rimoldi D; Fonteneau JF; Bonelo A; Liénard D; Rivoltini L; Jotereau F; Cerottini JC; Romero P
    J Immunol; 1998 Dec; 161(12):6956-62. PubMed ID: 9862730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
    Parkhurst MR; Salgaller ML; Southwood S; Robbins PF; Sette A; Rosenberg SA; Kawakami Y
    J Immunol; 1996 Sep; 157(6):2539-48. PubMed ID: 8805655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.
    Kawakami Y; Eliyahu S; Sakaguchi K; Robbins PF; Rivoltini L; Yannelli JR; Appella E; Rosenberg SA
    J Exp Med; 1994 Jul; 180(1):347-52. PubMed ID: 7516411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies.
    Denkberg G; Klechevsky E; Reiter Y
    J Immunol; 2002 Oct; 169(8):4399-407. PubMed ID: 12370373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.
    Borbulevych OY; Insaidoo FK; Baxter TK; Powell DJ; Johnson LA; Restifo NP; Baker BM
    J Mol Biol; 2007 Oct; 372(5):1123-36. PubMed ID: 17719062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partially modified retro-inverso pseudopeptides as non-natural ligands for the human class I histocompatibility molecule HLA-A2.
    Guichard G; Connan F; Graff R; Ostankovitch M; Muller S; Guillet JG; Choppin J; Briand JP
    J Med Chem; 1996 May; 39(10):2030-9. PubMed ID: 8642561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope.
    Bakker AB; van der Burg SH; Huijbens RJ; Drijfhout JW; Melief CJ; Adema GJ; Figdor CG
    Int J Cancer; 1997 Jan; 70(3):302-9. PubMed ID: 9033632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
    Cole DJ; Wilson MC; Rivoltini L; Custer M; Nishimura MI
    Cancer Res; 1997 Dec; 57(23):5320-7. PubMed ID: 9393756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
    Valmori D; Fonteneau JF; Lizana CM; Gervois N; Liénard D; Rimoldi D; Jongeneel V; Jotereau F; Cerottini JC; Romero P
    J Immunol; 1998 Feb; 160(4):1750-8. PubMed ID: 9469433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
    Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
    J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MHC allele-specific molecular features determine peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors.
    Wang Z; Turner R; Baker BM; Biddison WE
    J Immunol; 2002 Sep; 169(6):3146-54. PubMed ID: 12218132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes.
    Storkus WJ; Zeh HJ; Maeurer MJ; Salter RD; Lotze MT
    J Immunol; 1993 Oct; 151(7):3719-27. PubMed ID: 7690811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity.
    Keogh E; Fikes J; Southwood S; Celis E; Chesnut R; Sette A
    J Immunol; 2001 Jul; 167(2):787-96. PubMed ID: 11441084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.